Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12471147 | 1.00 | GAA (0.41) | GAAMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL11611264 | 0.92 | GAA (0.39) | GAAMAPT | |
| SCHEMBL11611273 | 0.92 | GAA (0.39) | GAAMAPT | |
| SCHEMBL448758 | 0.88 | GAA (0.44) | GAAMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL28264866 | 0.86 | GAA (0.43) | GAAMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL28986081 | 0.86 | GAA (0.43) | GAAMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL31079568 | 0.81 | GAA (0.39) | GAAMAPT | |
| SCHEMBL28596071 | 0.80 | MAPT (0.36) | GAAMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL1493703 | 0.79 | GAA (0.35) | GAAMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL28173102 | 0.77 | GAA (0.35) | GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100158905-A1 | COMBINATION THERAPY OF ARTHRITIS WITH TRANILAST | NUON THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158905-A1 | COMBINATION THERAPY OF ARTHRITIS WITH TRANILAST | PTGS2, PTGES2, PTGES | GAA 1793/4885MAPT 997/4885MEN1 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.